Number of the records: 1  

DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines

  1. 1.
    SYSNO ASEP0126967
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JOstatní články
    TitleDNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines
    Author(s) Kašpárková, Jana (BFU-R) RID, ORCID
    Marini, Victoria (BFU-R)
    Najajreh, Y. (IL)
    Gibson, D. (IL)
    Brabec, Viktor (BFU-R) RID, ORCID
    Source TitleBiochemistry. - : American Chemical Society - ISSN 0006-2960
    Roč. 42, č. 20 (2003), s. 6321-6332
    Number of pages12 s.
    Languageeng - English
    CountryUS - United States
    Keywordscross links ; DNA ; nonclassical platinum complexes
    Subject RIVBO - Biophysics
    R&D ProjectsIAA5004101 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
    KJB5004301 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
    GA305/01/0418 GA ČR - Czech Science Foundation (CSF)
    CEZAV0Z5004920 - BFU-R
    AnnotationThe global modification of mammalian and plasmid DNAs by novel platinum compounds, cis- or trans-[PtCl2(NH3)(Am)], where Am = NH3, nonplanar heterocycle piperidine, piperazine, or aromatic planar heterocycle 4-picoline, was investigated in cell-free media. These modifications have been compared with the activity of these new compounds in several tumor cell lines. The results show that the replacement of the NH3 group in cisplatin by the heterocyclic ligands does not considerably affect the DNA binding mode of this drug. In contrast to the analogues of cisplatin, the replacement of one ammine group by the heterocyclic ligand in its clinically ineffective trans isomer (transplatin) results in a radical enhancement of its activity in tumor cell lines. This replacement also markedly alters the DNA binding mode of transplatin.
    WorkplaceInstitute of Biophysics
    ContactJana Poláková, polakova@ibp.cz, Tel.: 541 517 244
    Year of Publishing2004

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.